Mission Bio Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
92
- Latest Deal Type
-
2ndary - Private
- Investors
-
25
Mission Bio General Information
Description
Developer of a precision genomics platform designed to provide single-cell targeted DNA sequencing at single-base resolution. The company's platform integrates targeted sequencing with protein expression profiling at single-cell resolution, supports detection of single-nucleotide and copy number variations, enables characterization of clonal heterogeneity and gene edits, and includes customizable panels and assay development services, enabling researchers and clinicians in oncology and cell therapy to uncover genetic diversity, improve therapeutic targeting, and accelerate biomarker discovery.
Contact Information
Website
www.missionbio.comCorporate Office
- 300 Utah Avenue
- Suite 210
- San Francisco, CA 94080
- United States
Corporate Office
- 300 Utah Avenue
- Suite 210
- San Francisco, CA 94080
- United States
Mission Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Secondary Transaction - Private | 01-Feb-2026 | Completed | Generating Revenue | |||
| 14. Later Stage VC | 04-Aug-2025 | Completed | Generating Revenue | |||
| 13. Later Stage VC (Series D) | 06-May-2022 | Completed | Generating Revenue | |||
| 12. Debt - General | 01-Jan-2022 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series C) | 13-Aug-2020 | Completed | Generating Revenue | |||
| 10. Grant | 12-Sep-2019 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B) | 13-Jul-2018 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 09-Jun-2017 | Completed | Generating Revenue | |||
| 7. Grant | 14-Feb-2017 | $100K | Completed | Startup | ||
| 6. Accelerator/Incubator | 01-Jan-2017 | $100K | $100K | Completed | Startup |
Mission Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 24,442,312 | $0.000010 | 8% | $1.23 | $1.23 | $1.23 | 18.13% | |
| Series A | 26,192,697 | $0.000010 | 8% | $0.55 | $0.55 | $0.55 | 19.43% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Mission Bio Comparisons
Industry
Financing
Details
Mission Bio Competitors (23)
One of Mission Bio’s 23 competitors is Sphere Fluidics, a Formerly VC-backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sphere Fluidics | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Nanion Technologies | Accelerator/Incubator Backed | Munich, Germany | ||||
| Genewiz | Formerly VC-backed | South Plainfield, NJ | ||||
| Standard BioTools | Formerly VC-backed | Boston, MA | ||||
| 1CellBio | Corporation | Cambridge, MA |
Mission Bio Patents
Mission Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023196928-A2 | True variant identification via multianalyte and multisample correlation | Inactive | 06-Apr-2022 | ||
| WO-2023196928-A3 | True variant identification via multianalyte and multisample correlation | Inactive | 06-Apr-2022 | ||
| WO-2023154816-A1 | Systems and methods of detecting merged droplets in single cell sequencing | Inactive | 09-Feb-2022 | ||
| WO-2023141604-A2 | Methods of molecular tagging for single-cell analysis | Inactive | 21-Jan-2022 | ||
| WO-2023141604-A3 | Methods of molecular tagging for single-cell analysis | Inactive | 21-Jan-2022 | C12Q1/6806 |
Mission Bio Signals
Mission Bio Investors (25)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Charles & Potomac Capital | Family Office | Minority | ||
| UCSF Innovation Ventures | Venture Capital | Minority | ||
| Ally Bridge Group | Growth/Expansion | Minority | ||
| Cambrian Growth Partners | Growth/Expansion | Minority | ||
| Dais Partners | Growth/Expansion | Minority |
Mission Bio FAQs
-
When was Mission Bio founded?
Mission Bio was founded in 2011.
-
Where is Mission Bio headquartered?
Mission Bio is headquartered in San Francisco, CA.
-
What is the size of Mission Bio?
Mission Bio has 92 total employees.
-
What industry is Mission Bio in?
Mission Bio’s primary industry is Discovery Tools (Healthcare).
-
Is Mission Bio a private or public company?
Mission Bio is a Private company.
-
What is Mission Bio’s current revenue?
The current revenue for Mission Bio is .
-
How much funding has Mission Bio raised over time?
Mission Bio has raised $212M.
-
Who are Mission Bio’s investors?
Charles & Potomac Capital, UCSF Innovation Ventures, Ally Bridge Group, Cambrian Growth Partners, and Dais Partners are 5 of 25 investors who have invested in Mission Bio.
-
Who are Mission Bio’s competitors?
Sphere Fluidics, Nanion Technologies, Genewiz, Standard BioTools, and 1CellBio are some of the 23 competitors of Mission Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process